Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Precision BioSciences Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners across 6 distinct art units, indicating broad distribution and limited repetition in the examiner assignments. The portfolio therefore requires coordination across several separate examination settings.
RAMIREZ, DELIA M is the busiest examiner, with 2 pending matters. Counsel should examine those matters for common treatment while maintaining separate analyses for the remaining assignments. Consistent biotechnology terminology, specification support, and claim-scope objectives can improve portfolio coherence, but the art-unit spread favors individualized responses to cited references and statutory grounds.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMIREZ, DELIA M | 1 | 65.1% | +56.3% |
| LEE, JAE W | 1 | 65.6% | +38.5% |
| ALLEN, SARAH ELIZABETH | 1 | 56.7% | +33.3% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| EMCH, GREGORY S | 1 | 48.0% | +43.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17933024 | COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS | ZHU, JIANJIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | ALLEN, SARAH ELIZABETH | 72d |
| 18793199 | NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE | RAMIREZ, DELIA M | — |
| 18605188 | RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF | LEE, JAE W | — |
| 17933024 | COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS | ZHU, JIANJIAN | — |
| 17819227 | OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES | KONOPKA, CATHERINE ANNE | — |
| 17782607 | METHODS FOR CANCER IMMUNOTHERAPY | EMCH, GREGORY S | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1656 | 1 |
| 1637 | 1 |
| 1631 | 1 |
| 1635 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18793199 | NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE | RAMIREZ, DELIA M | 1652 | §112Other | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18605188 | RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF | LEE, JAE W | 1656 | §102Other | Non-Final OA | — | Pending | Mar 14, 2024 |
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | ALLEN, SARAH ELIZABETH | 1637 | §103Other | Non-Final OA | 72d | Pending | Nov 10, 2022 |
| 17933024 | COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS | ZHU, JIANJIAN | 1631 | §102§103§112 | Non-Final OA | — | Pending | Sep 16, 2022 |
| 17819227 | OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES | KONOPKA, CATHERINE ANNE | 1635 | §112 | Non-Final OA | — | Pending | Aug 11, 2022 |
| 17782607 | METHODS FOR CANCER IMMUNOTHERAPY | EMCH, GREGORY S | 1678 | §103DP | Non-Final OA | — | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrecision BioSciences Inc. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Delia M Ramirez has the most, with 1 of Precision BioSciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
